Clinical Drug Experience Knowledgebase

babaodan (1 trial)

carvedilol (coreg) (2 trials)

cidan (1 trial)

cisatracurium (nimbex) (1 trial)

metuximab (2 trials)

nadroparin (1 trial)

rocuronium (zemuron) (1 trial)

vecuronium (norcuron) (1 trial)

warfarin (coumadin) (1 trial)

xihuang (1 trial)

131i-lipiodol (Lipiodol) (3 trials)

bortezomib (velcade) (1 trial)

cisplatin (platinol) (3 trials)

enoxaparin (lovenox) (1 trial)

epirubicin (ellence) (4 trials)

fluorouracil (efudex) (9 trials)

gelatin (1 trial)

indomethacin (indocin) (1 trial)

leucovorin (4 trials)

somatostatin (2 trials)

tremelimumab (Imjudo) (5 trials)

ak104 (2 trials)

anlotinib (1 trial)

autologous tumor infiltrating lymphocytes (1 trial)

bone marrow derived mesenchymal stem cells (1 trial)

carboplatin (paraplatin) (1 trial)

cd19 car-t cells (1 trial)

cetuximab (erbitux) (2 trials)

crizotinib (xalkori) (2 trials)

dendritic cell-precision multiple antigen t cells (3 trials)

dendritic cells (1 trial)

docetaxel (taxotere) (1 trial)

endostatin (endostar) (1 trial)

envafolimab (1 trial)

everolimus (zortress) (2 trials)

gefitinib (iressa) (2 trials)

gemcitabine (gemzar) (5 trials)

irinotecan (Camptosar) (2 trials)

lapatinib (tykerb) (3 trials)

mitomycin (mutamycin) (1 trial)

oxaliplatin (eloxatin) (5 trials)

pertuzumab (perjeta) (1 trial)

pik-her2 cell (1 trial)

pik-pd-1 cells (1 trial)

precision multiple antigen t cell (1 trial)

sorafenib (nexavar) (3 trials)

tegafur (2 trials)

toripalimab (LOQTORZ) (1 trial)

trastuzumab (herceptin) (3 trials)

tumor-pulsed dendritic cells (1 trial)

umbilical cord mesenchymal stem cells (1 trial)

s-adenosyl methionine (1 trial)

sirolimus (rapamune) (1 trial)

butorphanol (stadol) (1 trial)

chtnt-1 (1 trial)

entecavir (baraclude) (1 trial)

gimeracil (1 trial)

ginsenoside rg3 (3 trials)

glycyrrhizin (1 trial)

oteracil (1 trial)

pirarubicin (1 trial)

pregabalin (lyrica) (1 trial)

ulinastatin (1 trial)